Interactive effects of APOE haplotype, sex, and exercise on postheparin plasma lipase activities.
Hepatic lipase (HL) and lipoprotein lipase (LPL) activities (HLA, LPLA) modify lipoproteins and facilitate their binding to hepatic receptors. Apolipoprotein E (APOE) physically interacts with the lipases, and the three common haplotypes of the APOE gene (ε2, ε3, and ε4) yield protein isoforms (E2, E3, and E4, respectively) that are functionally different. Lipase activities themselves differ by sex and exercise training status. The interaction of APOE genotype, exercise training, and sex effects on lipase activities has not been studied. We measured postheparin plasma lipase activities in normolipidemic men and women with the three most common APOE genotypes, which are the haplotype combinations ε2/ε3 (n = 53 ), ε3/ε3 (n = 62), and ε4/ε3 (n = 52), enrolled in 6 mo of aerobic exercise training. These haplotype combinations comprise an estimated 11.6, 62.3, and 21.3% of the population, respectively. Baseline HLA was 35% lower in women than in men (P < 0.0001). In men but not women, HLA was higher in ε2/ε3 group compared with ε4/ε3 (P = 0.01) and ε3/ε3 (P = 0.05). Neither sex nor APOE genotype affected baseline LPLA. Training decreased HLA by 5.2% (P = 0.018) with no APOE effect. The apparent increase in LPLA following exercise was significant and APOE dependent only when corrected for baseline insulin (P < 0.05). Exercise decreased LPLA by 0.8 μmol free fatty acid (FFA)·ml⁻¹·h⁻¹ (-6%) in ε3/ε3 compared with the combined increases of 6.6% in ε2/ε3 and 12% in ε4/ε3 (P = 0.018 vs. ε3/ε3). However, these differences were statistically significant only after correcting for baseline insulin. We conclude that common APOE genotypes interact with 1) sex to modulate HLA regardless of training status, with ε2/ε3 men demonstrating higher HLA than ε3/ε3 or ε4/ε3 men, and 2) aerobic training to modulate LPLA, regardless of sex, with ε3/ε3 subjects showing a significant decrease compared with an increase in ε2/ε3 and ε3/ε4 after controlling for baseline insulin.
Preventive Cardiology-JB704, Hartford Hospital, Hartford, CT 06102-5037, USA. rseip@harthosp.org
Richard L
RL
Seip
Robert F
RF
Zoeller
Theodore J
TJ
Angelopoulos
James
J
Salonia
Cherie
C
Bilbie
Niall M
NM
Moyna
Mary P
MP
Miles
Paul S
PS
Visich
Linda S
LS
Pescatello
Paul M
PM
Gordon
Gregory J
GJ
Tsongalis
Linda
L
Bausserman
Paul D
PD
Thompson
D000704:Analysis of Variance; D001057:Apolipoproteins E / Q000097:blood / Q000235:genetics*; D015444:Exercise / Q000502:physiology*; D005260:Female; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood* / Q000235:genetics; D008297:Male; D012307:Risk Factors; D012737:Sex Factors
D001057:Apolipoproteins E; D007328:Insulin; D008055:Lipids; D008071:Lipoprotein Lipase
Am J Hum Genet. 2002 Sep;71(3):501-17
12165926
Endocrinology. 1997 Sep;138(9):3779-86
9275065
J Lipid Res. 2004 Mar;45(3):551-60
14679168
Biochemistry. 1992 Mar 3;31(8):2332-8
1540589
JAMA. 2007 Sep 19;298(11):1300-11
17878422
Biochemistry. 1973 Apr 24;12(9):1828-33
4349259
J Biol Chem. 1994 Sep 2;269(35):22358-65
8071364
Atherosclerosis. 2003 Jul;169(1):63-70
12860251
Curr Vasc Pharmacol. 2003 Mar;1(1):11-7
15320848
Metabolism. 1995 Aug;44(8):965-71
7637653
Physiol Res. 2003;52(2):195-200
12678662
Metabolism. 1999 Aug;48(8):943-5
10459553
Metabolism. 2004 Jan;53(1):108-16
14681851
J Lipid Res. 2000 Aug;41(8):1290-301
10946017
J Lipid Res. 2002 Aug;43(8):1163-9
12177160
J Biol Chem. 1985 Oct 5;260(22):11934-43
2995353
J Clin Invest. 1977 Apr;59(4):601-8
845252
Curr Opin Lipidol. 1999 Jun;10(3):207-17
10431657
Arterioscler Thromb Vasc Biol. 1997 Aug;17(8):1545-9
9301634
Atherosclerosis. 2006 Sep;188(1):126-33
16842800
Curr Opin Lipidol. 1997 Feb;8(1):43-52
9127711
Med Sci Sports Exerc. 1980;12(3):175-81
7402053
J Lipid Res. 1999 Feb;40(2):229-34
9925651
J Biol Chem. 1997 Sep 5;272(36):22685-94
9312550
FEBS Lett. 1989 Jul 17;251(1-2):250-2
2546823
J Lipid Res. 1995 Apr;36(4):839-59
7616127
Arterioscler Thromb Vasc Biol. 2002 Jan;22(1):133-40
11788473
J Lipid Res. 1999 Mar;40(3):432-8
10064731
Atherosclerosis. 1998 Dec;141 Suppl 1:S1-7
9888635
Science. 2001 Jul 20;293(5529):489-93
11452081
J Lipid Res. 2002 Sep;43(9):1363-79
12235168
Metabolism. 2004 Feb;53(2):193-202
14767871
Hum Mol Genet. 2002 Jun 1;11(12):1477-85
12023990
Proc Natl Acad Sci U S A. 1984 Sep;81(17):5566-70
6591204
Am J Clin Nutr. 2000 Jun;71(6):1390-1
10837276
Br J Nutr. 1978 Nov;40(3):497-504
718832
J Clin Invest. 1985 Feb;75(2):710-21
3973025
Biochemistry. 2000 Mar 28;39(12):3433-40
10727238
Clin Chem. 1994 Jan;40(1):24-9
8287539
Am J Cardiol. 1993 Jan 15;71(2):160-5
8421977
Exerc Sport Sci Rev. 1998;26:191-218
9696990
Atherosclerosis. 1988 Sep;73(1):45-55
3178931
Metabolism. 1997 Feb;46(2):217-23
9030832
Exerc Sport Sci Rev. 1994;22:477-521
7925552
Biochem Soc Trans. 2003 Oct;31(Pt 5):1070-4
14505482
Clin Lab. 2003;49(11-12):601-13
14651331
Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1750-4
15284087
Med Sci Sports Exerc. 1999 May;31(5):692-7
10331889
J Cardiopulm Rehabil. 2002 Nov-Dec;22(6):385-98
12464825
Metabolism. 1996 Jul;45(7):797-803
8692011
Arterioscler Thromb. 1991 Sep-Oct;11(5):1303-9
1911716
Curr Opin Lipidol. 1996 Aug;7(4):209-16
8883496
Circ Res. 1973 Oct;33(4):403-11
4355035
J Clin Invest. 1991 Nov;88(5):1490-501
1939641
Biochemistry. 2003 Aug 26;42(33):9841-53
12924933
J Biol Chem. 1982 Mar 10;257(5):2518-21
6277903